Probiotic-based therapy for ulcerative colitis (UC) is a novel and promising approach that
has gained much popularity in recent years. However, probiotics may be easily captured …

Despite the great progress of current bacterially based biotherapeutics, their unsatisfying
efficacy and underlying safety problems have limited their clinical application. Herein …

Microbiota‐based therapeutics offer innovative strategies to treat inflammatory bowel
diseases (IBDs). However, the poor clinical outcome so far and the limited flexibility of the …

Inflammatory bowel disease (IBD) is an incurable disease of the gastrointestinal tract with a
lack of effective therapeutic strategies. The proinflammatory microenvironment plays a …

It is of great significance to eliminate excessive reactive oxygen species (ROS) for treating
inflammatory bowel disease (IBD). Herein, for the first time, a novel nanozyme NiCo2O4 …

The gut microbiota are prominent in preserving intestinal environmental homeostasis and
managing human health, and their dysbiosis has been directly related to many kinds of …

As a recurrent chronic inflammatory intestinal disease, ulcerative colitis (UC) has seriously
affected the life quality of patients. Numerous studies have demonstrated excessive reactive …

Antibiotic therapeutics to combat intestinal pathogen infections often exacerbate microbiota
dysbiosis and impair mucosal barrier functions. Probiotics are promising strategies, because …

Inflammatory bowel disease (IBD) affects millions of individuals worldwide annually. Enteric
reactive oxygen species (ROS) play critical roles in the physiology and pathology of IBD …

While oral probiotics show promise in treating inflammatory bowel disease, the primary
challenge lies in sustaining their activity and retention within the inflamed gastrointestinal …